DCAF7 and lung adenocarcinoma: Pan‐cancer analysis in Tumor Immune Estimation Resource 2.0 (TIMER2.0) demonstrated significant DCAF7 up‐regulation in bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), oesophageal carcinoma, head‐and‐neck squamous cell carcinoma (HNSC), LIHC, lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), rectum adenocarcinoma, stomach adenocarcinoma (STAD) and uterine corpus endometrial carcinoma (UCEC) patients (Figure 1A).